scholarly journals Relative Frequencies and Patterns of Malignant Lymphoma in a Reference Centre in Khartoum, Sudan: A Descriptive Study Based on the WHO Classification of Lymphoid Neoplasms

2020 ◽  
Vol 5 (2) ◽  
pp. 107-112
Author(s):  
Ezeldine K Abdalhabib
Keyword(s):  
B Cell ◽  
Malignant Lymphoma ◽  
Complete Blood Count ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Reference Centre ◽  
Large B Cell Lymphoma ◽  
Appropriate Treatment ◽  
Age Range ◽  
Large B Cell

Background: The effective management and choice of appropriate treatment of lymphoma subtypes depend on an accurate diagnosis and differentiation, which require comprehensive haematology and pathology work. Methods: A total of 134 cases of malignant lymphoma, newly diagnosed between January 2017 to January 2020, were selected. For each patient’s samples, complete blood count, immunohistochemistry, and morphological evaluation were done. Results: Clinical data showed that 81 patients (60.4%) were males and 53 (39.6%) females. The age range was 4 to 80 years. NHL lymphoma comprised 87.3% of cases, while HL comprised 12.7% of cases. Diffuse large B cell lymphoma was the most prevalent NHL subtype, representing 39.3% of cases. Among HL subtypes, mixed cellularity was present in 41.2% of cases. B cell lymphoma constituted 93.2% of cases. All HL patients and 74.4% of NHL patients had anaemia. Conclusion: This is the first statistical report of malignant lymphoma patterns in Sudanese patients. These data suggest that malignant lymphoma in Sudanese patients is more frequent in males than females; its incidence increases with age. Further, B cell lymphoma is more common than T cell lymphoma. Diffuse large B cell lymphoma was the most frequent NHL subtype.

scholarly journals Primary Type3 (Non-ABC, Non-GCB) Subtype of Extranodal Diffuse Large B-Cell Lymphoma of the Thyroid Bearing No MYD88 Mutation by Padlock Probe Hybridization

2017 ◽  
Vol 10 (2) ◽  
pp. 508-514 ◽  
Author(s):  
Yukiko Nishi ◽  
Riko Kitazawa ◽  
Ryuma Haraguchi ◽  
Ayaka Ouchi ◽  
Yasuo Ueda ◽  
...  
Keyword(s):  
B Cells ◽  
B Cell ◽  
Malignant Lymphoma ◽  
Cell Lymphoma ◽  
Clinical Phenotype ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Japanese Female ◽  
Old Japanese ◽  
Large B Cell

Primary extranodal malignant lymphoma of the thyroid is a rare entity composed of mostly neoplastic transformation of germinal center-like B cells (GCB) or memory B cells. Other B-cell-type malignancies arising primarily in the thyroid have rarely been described. Immunohistochemical examination of autopsied primary malignant lymphoma of the thyroid in an 83-year-old Japanese female revealed the presence of a non-GCB subtype of diffuse large B-cell lymphoma (DLBCL) without the typical codon 206 or 265 missense mutation of MYD88. The lack of the highly oncogenic MYD88 gene mutation, frequently observed in DLBCL of the activated B-cell (ABC) subtype, and the detection of an extremely aggressive yet local clinical phenotype demonstrated that the present case was an exceptional entity of the type3 (non-GCB and non-ABC) subtype.

Intensive Chemotherapy in the Treatment of Aggressive Diffuse Large B-Cell Lymphoma: Malignant Lymphoma

2004 ◽  
Vol 21 (3) ◽  
pp. 269-272 ◽  
Author(s):  
Agustin Avilés ◽  
M. Jesús Nambo ◽  
Natividad Neri ◽  
Alejandra Talavera ◽  
Claudia Castañeda ◽  
...  
Keyword(s):  
B Cell ◽  
Malignant Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Intensive Chemotherapy ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Diffuse large B cell lymphoma of submandibular gland in a seropositive case – a rare presentation

2017 ◽  
Vol 5 (5) ◽  
pp. 2257
Author(s):  
Rachana S. Binayke ◽  
Kalpana A. Deshpande
Keyword(s):  
B Cell ◽  
Malignant Lymphoma ◽  
Salivary Glands ◽  
Submandibular Gland ◽  
Cell Lymphoma ◽  
Cervical Lymphadenopathy ◽  
B Cell Lymphoma ◽  
Histopathological Diagnosis ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Lymphomas account for 2%-5% of salivary gland neoplasms. The parotid gland is the most commonly involved, constituting 70% of the cases, followed by submandibular gland (25%), sublingual and minor salivary glands (<10%). In present study a 56 years old seropositive male presented with a submandibular gland swelling of 2 months duration; along with multiple cervical lymphadenopathy. Grossly a single, well encapsulated, grayish-white tissue measuring 3x2.5x2 cms was received. It was solid, grayish-white on cut section. Histology revealed features of diffuse large B cell lymphoma with myoepithelial sialadenitis. Immunohistochemistry showed positivity for LCA & CD20, thus confirming the histopathological diagnosis. Primary malignant lymphoma of salivary glands is uncommon. Inspite of malignant lymphoma being the second most common AIDS-associated neoplasm, it’s occurrence in submandibular gland is extremely rare.

scholarly journals Collision Tumor Comprising Primary Malignant Lymphoma and Adenocarcinoma in the Ascending Colon

2021 ◽  
pp. 379-388
Author(s):  
Jun Kataoka ◽  
Toshikatsu Nitta ◽  
Masato Ota ◽  
Kensuke Fujii ◽  
Masatsugu Ishii ◽  
...  
Keyword(s):  
Lymph Node ◽  
B Cell ◽  
Malignant Lymphoma ◽  
Cell Lymphoma ◽  
Muscularis Propria ◽  
B Cell Lymphoma ◽  
Collision Tumor ◽  
Ascending Colon ◽  
Large B Cell Lymphoma ◽  
Large B Cell

We describe the case of a 78-year-old man with collision tumor from the primary malignant lymphoma and adenocarcinoma in the ascending colon. He suffered anemia from sigmoid colon cancer, and colonoscopy revealed early-stage colorectal cancer with a diameter of 20 mm in the cecum, the biopsy specimen showed moderately differentiated adenocarcinoma. Contrast-enhanced computed tomography (CT) revealed bowel wall thickening with contrast enhancement at the cecum; however, no lymph node and organ metastases were found. As above, we performed laparoscopic ileocecal resection with D3 lymph node dissection. The postoperative course was uneventful, and he was discharged from the hospital on postoperative day 11. Histopathological findings were moderately differentiated adenocarcinoma which invaded the muscularis propria and serosa from the submucosa, while the adjacent serosa showed a highly diffuse proliferation of atypical cells with an irregular nuclear-to-cytoplasmic ratio. Besides, immunohistochemical staining findings were diffuse large B-cell lymphoma, and diffuse large B-cell lymphoma was coexistent with moderately differentiated adenocarcinoma. We treated the patient with cyclophosphamide, doxorubicin, vincristine, and prednisolone in combination with rituximab (R-CHOP therapy) during 3 months postoperatively. When the 8 courses had been completed, postoperative positron emission tomography-CT (PET-CT) confirmed complete response, and the disease control has been doing well. Malignant lymphoma of the colorectal region is relative rare, and the occurrence of synchronous lymphoma and adenocarcinoma of the colon is also rare. Furthermore, collision tumor by these different entities is very unusual. We presented here such a case. The accurate clinical determination of the dominant tumor and a close follow-up is required for proper treatment in these cases.

A Phase II Trial of Alemtuzumab (Campath) with DA-EPOCH-R in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 3709-3709 ◽  
Author(s):  
Cliona Grant ◽  
Kieron Dunleavy ◽  
Julieanne Hessler ◽  
Seth M. Steinberg ◽  
Stefania Pittaluga ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Mononuclear Cells ◽  
Conflicts Of Interest ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Complete Response ◽  
Large B Cell Lymphoma ◽  
Age Range ◽  
Large B Cell

Abstract Abstract 3709 Background: In diffuse large B-cell lymphoma (DLBCL), stromal signatures are predictive of outcome in newly diagnosed patients treated with R-CHOP. These signatures, termed 'stromal 1' and 'stromal 2' are associated with genes expressed by infiltrating mononuclear cells. The stromal 2 signature includes genes associated with angiogenesis and is associated with a poor outcome. Hence, targeting reactive cells in the microenvironment is a rational therapeutic strategy in DLBCL. In Hodgkin lymphoma (HL), the reactive macrophages surrounding Hodgkin Reed Sternberg (HRS) cells are associated with an adverse outcome and may provide survival signals. CD52 is highly expressed in many of these cells in the microenvironment and in most cases of DLBCL. Methods: We combined alemtuzumab (a monoclonal antibody against CD52) with DA-EPOCH-R to target reactive cells in the microenvironment and positive tumor cells. Alemtuzumab (30 mgs on day 1) was administered intravenously before DA-EPOCH-R (as previously described) and responding patients received up to 6 cycles of therapy. Results: Characteristics of 28 patients accrued: median age (range) 44 (22–72); male sex 15 (54%); stage III or IV disease 20 (71%); median prior regimens (range) 2 (1–6); and prior autologous transplant 7 (25%). Enrolled histologies were HL 12 (43%); DLBCL 10 (36%); and primary mediastinal B-cell lymphoma 6 (21%). Responses by histological subtype are shown in the attached table. The regimen was particularly effective in patients with HL with a CR rate of 73%. At 12 months (with 21 months median potential follow-up), the OS and PFS probabilities for all patients were 68% and 18% respectively. Toxicities included: treatment related mortality (sepsis) in 1 patient; febrile neutropenia in 16%; and grade 4 thrombocytopenia 15% of cycles. CMV reactivation was observed in 52% of patients in the setting of anti-viral prophylaxis. Conclusions: Combining alemtuzumab with DA-EPOCH-R is feasible. Patients with a diagnosis of HL had a very high complete response rate. Accrual continues. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document